Introduction
============

Chronic obstructive pulmonary disease (COPD) is characterized by progressive and irreversible expiratory flow limitation and dyspnea. In patients with COPD, frequent exacerbations are the most prominent and distressing symptom.[@b1-copd-10-1343] Patients with COPD may be particularly vulnerable to reflux and gastroesophageal reflux disease (GERD), which is common in advanced COPD. Although little is known about the prevalence and role of GERD in COPD, exaggerated intrathoracic pressure shifts, increased frequency of coughing, diaphragmatic flattening, and use of β2-agonists are thought to exacerbate reflux.[@b2-copd-10-1343],[@b3-copd-10-1343] However, patients with respiratory disease are often asymptomatic for reflux, and show isolated abnormal proximal reflux, resulting in symptoms that lack sufficient sensitivity and specificity to reliably diagnose or exclude GERD.[@b4-copd-10-1343],[@b5-copd-10-1343]

Laryngopharyngeal reflux (LPR) is considered a different disease from classic reflux or GERD. It is believed that the primary defect in LPR might be upper esophageal sphincter dysfunction in less than half of LPR patients with GERD.[@b6-copd-10-1343] Most patients with LPR have throat symptoms like dysphonia, chronic cough, globus pharyngeus, and chronic throat clearing.[@b7-copd-10-1343] A diagnosis of LPR may be established by interviewing patients and questioning about specific symptoms, videolaryngoscopic evaluation of the larynx, or double probe pH monitoring.[@b8-copd-10-1343]--[@b10-copd-10-1343] Ambulatory 24-hour double probe (pharyngeal and esophageal) pH monitoring is highly sensitive and specific for the diagnosis of LPR.[@b11-copd-10-1343] While pH monitoring is not widely available in clinical practice due to its inconvenience and cost, videolaryngoscopic examination is more easily accessible. Therefore, if a clinical diagnosis of LPR in patients with COPD is identified, physicians may have a valuable tool in the management of reflux-related disease in COPD.

Considering the fact that COPD may exacerbate gastroesophageal reflux, LPR can be aggravated by similar mechanisms. However, limited studies have investigated the association between LPR and COPD or the clinical significance of LPR in patients with COPD. In addition, previous studies have focused on the effect of LPR treatment on COPD, and shown that treatment of LPR resulted in significant improvement in symptoms of COPD.[@b12-copd-10-1343] In contrast, a study of LPR and asthma showed that reflux symptom score and LPR disease index are not reliable for diagnosing LPR in patients with asthma.[@b13-copd-10-1343] In this present study, we aimed to assess the prevalence of LPR in COPD patients, stage the LPR severity, and correlate findings/symptoms with indices of COPD.

Materials and methods
=====================

Study population
----------------

All of the patients enrolled in the study were recruited from March 2013 to July 2014 at routine follow-up visits to the pulmonary clinic, located at an academic hospital in South Korea. The inclusion criteria required participants to be aged 40 years or older, diagnosed with COPD based on guidelines,[@b1-copd-10-1343] have a smoking history of over ten packs/year, and be able to provide written informed consent. Exclusion criteria included previous diagnosis of LPR or GERD, recent history of exposure to proton pump inhibitors within 2 months, airflow limitation resulting from parenchymal destruction with previous infection (eg, pulmonary tuberculosis, diffuse bronchiectasis), a recent history of alcohol abuse, known esophageal disease including cancer, achalasia and peptic ulcer disease, and any clinically significant concurrent disease. COPD patients with exacerbation within 1 month of enrollment were also excluded. The institutional review board (approval 06-2011-72) of Seoul National University Boramae Medical Center approved all of the protocols and study design, and all patients gave written informed consent. Data on demographic, physiologic, and clinical characteristics, including age, sex, height, body weight, smoking status, spirometric data, and use of respiratory medications, were obtained from each patient.

Study protocol
--------------

This cross-sectional study evaluated the prevalence of LPR in COPD patients, and prospectively observed the patients for 1 year after enrollment to measure the frequency of acute exacerbations of COPD (AECOPD). On enrolment, patients were surveyed with the modified Medical Research Council dyspnea scale and laryngeal symptom index (RSI).[@b8-copd-10-1343],[@b14-copd-10-1343] Spirometric data were also collected. Patients were regularly followed at 2, 6, and 12 months after initial registration. The number of acute moderate or severe exacerbations were evaluated at each follow-up. The severity of AECOPD was determined by the requirement for antibiotics or systemic steroids (moderate) and admission to hospital due to exacerbation (severe).

Laryngoscopy was performed by an otolaryngologist (YHJ) and interpreted by two independent otolaryngologists (YHJ and DYL). Reflux finding scores (RFS) were summated by calculating the score of each of the findings, ie, subglottic edema (0/2), vocal fold edema (0/1/2/3/4), ventricular obliteration (0/2/4), diffuse laryngeal edema (0/1/2/3/4), erythema/hyperemia (0/2/4), posterior commissure hypertrophy (0/1/2/3/4), thick mucus (0/2), and granuloma (0/2). LPR was defined as an RFS over 7 and an RSI over 13.[@b8-copd-10-1343],[@b10-copd-10-1343]

To compare RFS and RSI of non-COPD controls, 32 age-matched and sex-matched normal controls who had routine health check-ups during the study period were included. The controls also did not have a previous history of GERD or LPR, and any pulmonary disease was ruled out by chest X-ray and pulmonary function testing.

Statistical analysis
--------------------

Continuous variables were presented as the mean ± standard deviation, and categorical variables as frequencies and group percentages. Continuous variables were compared according to the severity of airflow limitation (Global Initiative for Chronic Obstructive Lung Disease grade) and acute exacerbation of COPD by independent samples *t*-test or analysis of variance test. Categorical variables were compared using chi-square analysis or a Cochran-Armitage trend test. RFS and RSI were considered both continuous and categorical variables (RFS positive \>7 and negative ≤7, RSI positive \>13 and negative ≤13). The established risk factors for exacerbations were included in a bivariate logistic regression analysis model. The odds ratios and 95% confidence intervals were then calculated. *P*\<0.05 was considered to be statistically significant. The statistical analysis was performed using Statistical Package for the Social Sciences version 20.0 software (SPSS Inc, Chicago, IL, USA).

Results
=======

Characteristics of study population
-----------------------------------

The detailed characteristics of the study population are summarized in [Table 1](#t1-copd-10-1343){ref-type="table"}. A total of 118 patients with COPD were enrolled. The mean age was 69.2±8.8 years and the male to female ratio was 110:8. The mean follow-up duration was 14.3±5.4 months. According to the Global Initiative for Chronic Obstructive Lung Disease classification, patients were categorized into four groups: A, low risk with less symptoms (n=27, 22.9%); B, low risk with more symptoms (n=45, 38.1%); C, high risk with less symptoms (n=13, 11.0%); and D, high risk with more symptoms (n=33, 28.0%). The four groups showed no significant difference in age, sex ratio, or body mass index. The follow-up duration was significantly shorter in group A (*P*=0.008; [Table 2](#t2-copd-10-1343){ref-type="table"}). In the entire cohort, moderate and severe AECOPD was observed in 23 (19.5%) and 15 patients (12.7%), respectively. Both moderate and severe AECOPD were more frequent in groups C and D than in groups A and B (*P*\<0.001; [Table 2](#t2-copd-10-1343){ref-type="table"}). The mean RFS and RSI were 6.86±2.60 and 4.57±4.71, respectively. Positive RFS (\>7) and RSI (\>13) were observed in 51 (42.5%), and six (5.0%) patients, respectively. Only five patients (4.2%) were diagnosed with LPR by RFS and RSI criteria. Comparing the area under receiver operating curve for RSI, 8.5 points of RSI coincided with the cut-off value of RSI (7 points) for LPR, which was lower than the usual cut-off value of RSI (13 points) for LPR.

Association between LPR parameters, AECOPD, and dyspnea severity
----------------------------------------------------------------

When comparing the low-risk groups (A and B) and the high-risk groups (C and D), the total RFS and RSI were not significantly different (*P*=0.344 and *P*=0.252, respectively), although positive correlations in trends were suggested in each parameter for LPR ([Table 3](#t3-copd-10-1343){ref-type="table"}). With regard to the RFS parameter, diffuse laryngeal edema and erythema/hyperemia showed significantly higher scores in the high-risk groups than in the low-risk groups (*P*=0.025 and *P*=0.049, respectively). Patients with RSI \>3 were more prevalent in the high-risk groups (*P*=0.032). When comparing the groups with less symptoms (groups A and C) with the groups with more symptoms (groups B and D), RFS and each of the parameters showed no significant difference ([Table 3](#t3-copd-10-1343){ref-type="table"}). However, total RSI was significantly higher in the groups with more symptoms (*P*=0.047), and there were more patients with RSI \>8.5 in the groups with more symptoms (*P*=0.006).

Multivariate analysis revealed that no parameter was significantly associated with acute moderate exacerbation. However, both RSI (continuous or dichotomous) and RFS (continuous) were significantly associated with acute severe exacerbation (*P*=0.03, *P*=0.01, and *P*=0.047, respectively; [Table 3](#t3-copd-10-1343){ref-type="table"}). There was a significant negative correlation between RFS and residual volume/total lung capacity (%) in simple correlation analysis (*P*=0.048), while correlation of RFS and RSI with forced expiratory volume in 1 second (FEV~1~; %), residual volume/total lung capacity (%), and diffusing capacity of the lungs for carbon monoxide (%) showed no significant correlation ([Figure 1](#f1-copd-10-1343){ref-type="fig"}). With regard to the severity of dyspnea measured with the modified Medical Research Council scale, RSI was a significant predictor for severe dyspnea after adjusting for age, sex, body mass index, and FEV~1~% predicted ([Table 4](#t4-copd-10-1343){ref-type="table"}).

Comparison between COPD patients and normal controls
----------------------------------------------------

Normal controls showed mean RFS and RSI scores of 3.13±2.83 and 3.25±3.57, respectively. RFS and RSI were significantly higher in patients with COPD (*P*\<0.001; [Figure 2](#f2-copd-10-1343){ref-type="fig"}). RFS findings indicated that, subglottic edema, vocal fold edema, ventricular obliteration, diffuse laryngeal edema, and posterior commissure hypertrophy were significantly prevalent or more severe in patients with COPD than in normal controls ([Table 5](#t5-copd-10-1343){ref-type="table"}, [Figure 3](#f3-copd-10-1343){ref-type="fig"}).

Discussion
==========

GERD is a well-known comorbidity of COPD,[@b12-copd-10-1343],[@b15-copd-10-1343] and is negatively associated with symptoms, quality of life, and exacerbation of COPD.[@b16-copd-10-1343]--[@b18-copd-10-1343] However, the association between COPD and LPR, a laryngeal manifestation and airway effect of GERD, has not been extensively studied. To the best of our knowledge, this is the first report of an association between LPR and AECOPD. In the course of this study, we identified features of LPR in patients with COPD.

The prevalence of GERG reported has been varied in studies, according to differences in study population and diagnostic definition. Self-reported GERD was found in 29% of patients in the COPDGene study cohort,[@b18-copd-10-1343] and 28% of COPD patients reported GERD in a nationwide health insurance data survey.[@b15-copd-10-1343] We excluded patients with alleged gastric disorders, and RFS-based LPR was found in 42.5% of patients, whereas RSI-defined LPR was identified in only 5.0% of patients with COPD in this study. Although the prevalence of LPR in COPD has rarely been reported in large populations, RFS-defined LPR was higher than expected considering that LPR may be a part of GERD. Nevertheless, it has been reported that in severe COPD, pathologic reflux, as defined by pH monitoring, was increased in up to 62% of subjects. Consistent with our results, 58% of these patients did not report any reflux symptoms.[@b18-copd-10-1343],[@b19-copd-10-1343] In other words, symptom-defined prevalence may be lower than objectively-defined pathologic findings. The correlation between RFS and RSI was low in our study group, even considering the small number of subjects ([Figure S1](#SD1-copd-10-1343){ref-type="supplementary-material"}). There are two hypotheses: First, the common respiratory symptoms of COPD can be presented with those in RSI such as dysphonia, throat clearing, excess throat mucus, and cough. As a result, any symptoms they may be experiencing could be ignored or attributed to more common daily symptoms rather than LPR. Supporting our hypothesis, the number of patients with an RSI \>13 (the cut-off value for LPR in the general population) was very small in the main analysis and additive analysis when compared with normal controls, although the mean difference in RSI was significantly different ([Figure 2A](#f2-copd-10-1343){ref-type="fig"}). In contrast, the number of patients with RFS greater than 7 (the cutoff value for LPR in the general population) was more prevalent in COPD patients ([Figure 2B](#f2-copd-10-1343){ref-type="fig"}). Second, there is a possibility of overdiagnosis of RFS. However, the second explanation may be less likely considering that the prevalence of symptomatic GERD was lower than that measured by ambulatory pH monitoring,[@b19-copd-10-1343] and a higher prevalence and more severe grade of RFS was identified in patients with COPD ([Table 5](#t5-copd-10-1343){ref-type="table"}) when compared with age-matched and sex-matched normal subjects. In this respect, LPR findings in COPD could be an indicator of acid reflux rather than reflux symptoms in patients with COPD.

We found that RFS and RSI were associated with severe AECOPD independent of age, sex, FEV~1~, or body mass index. In addition, the prevalence and grade of RFS and severity of RSI increased according to the increasing COPD severity; the failure of this association to reach statistical significance could be attributable to the small number of subjects.

AECOPD is a major treatment target in COPD,[@b20-copd-10-1343] and many contributing factors have been reported, including GERD.[@b21-copd-10-1343],[@b22-copd-10-1343] Our study is the first to examine the possible relationship between LPR and AECOPD. Dysfunction of the upper esophageal sphincter (UES) is considered a critical pathogenic step in LPR, and is also associated with dysfunction of the UES as well as the lower esophageal sphincter, as shown in an esophageal motility study.[@b23-copd-10-1343] The role of the UES is more emphasized during coughing, and is important in preventing esophagopharyngeal reflux during cough, even in elderly people.[@b24-copd-10-1343] Hyperinflation-induced poor exercise capacity, higher intrathoracic pressure, and flattening of the diaphragm are expected to contribute to the pathogenesis of GERD in COPD.[@b2-copd-10-1343],[@b3-copd-10-1343] If a similar mechanism occurred in patients with LPR, the increased residual volume (145.6% of predicted value) in our study population can be explained by the proposed mechanism. Moreover, our findings demonstrate that the residual volume/total lung capacity (%) was significantly correlated with RFS. This supports the previous theory concerning the correlation between LPR and COPD, along with the association of COPD with reflux findings rather than reflux symptoms as mentioned previously. Among the RFS, diffuse laryngeal edema and erythema/hyperemia showed significantly higher scores in the high-risk group. Subglottic edema and posterior commissure hypertrophy were typical and frequent findings in LPR patients without COPD (data not shown). We consider that these findings could be unique for COPD, especially for the high-risk groups.

The present study had some limitations. First, as mentioned earlier, it had weak statistical power due to the small number of patients and had a lack of generalizability due to the preponderance of male subjects. We tried to exclude patients with alleged reflux-related gastrointestinal disease and those who had used proton pump inhibitors. A high prevalence of GERD and prevalent use of proton pump inhibitors led us to restrict the enrolled numbers of study subjects. As a result, statistical power was not achieved for some parameters. Second, a therapeutic trial with proton pump inhibitors and follow-up laryngeal examination were not performed in this study. Thus, the clinical significance of each RFS finding cannot be discussed. Third, RSI and RFS could have limited sensitivity and specificity for diagnosing the LPR. The innate weakness in diagnosing LPR is that there is no diagnostic method of gold standard yet. Although double probe pH monitoring could be used for suspicious patients, poor cooperation of the patients from discomfort during the test and lack of strong correlation with the LPR symptom limit the wide appliance of the double probe pH monitoring. In this study, diagnostic definition of LPR was based on RSI and RFS, because those parameters were validated in terms of the correlation and response to treatment.

Conclusion
==========

In summary, laryngeal reflux findings were prevalent in patients with COPD, and were found in 42.5% of subjects in this study. RFS and RSI for LPR indicated significant risk factors for AECOPD. Laryngeal examination may be clinically indicated during AECOPD, and further studies of LPR in COPD patients should be considered.

Supplementary material
======================

###### 

Correlation between RFS and RSI in patients with COPD.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; RFS, reflux finding score; RSI, reflux symptom index.
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![Correlation of reflux symptom index and finding score with post FEV~1~ (%) (**A**, **B**), RV/TLC (%) (**C**, **D**), and DL~CO~ (%) (**E**, **F**) in patients with COPD.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; DL~CO~, carbon monoxide diffusing capacity; FEV~1~, forced expiratory volume in 1 second; RFS, reflux finding score; RSI, reflux symptom index; RV, residual volume; TLC, total lung capacity.](copd-10-1343Fig1){#f1-copd-10-1343}

![RSI (**A**) and RFS (**B**) of patients with COPD and a normal control.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; RFS, reflux finding score; RSI, reflux symptom index.](copd-10-1343Fig2){#f2-copd-10-1343}

![Reflux finding score of patients with COPD and normal controls.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; DLE, diffuse laryngeal edema; EH, erythema/hyperemia; PCH, posterior commissure hypertrophy; SGE, subglottic edema; VFE, vocal fold edema; VO, ventricular obliteration.](copd-10-1343Fig3){#f3-copd-10-1343}

###### 

Characteristics of COPD patients (n=118)

  ------------------------------------------------------------------------------------------ --------------
  Age, years, mean (± SD)                                                                    69.2 (±8.8)
  Sex (M:F)                                                                                  110:8
  Follow-up duration (months), mean (± SD)                                                   14.3 (±5.4)
  BMI (kg/m^2^), mean (± SD)                                                                 22.1 (±3.2)
  Dyspnea (mMRC), mean (± SD)                                                                1.82 (±0.70)
  Spirometry, mean (± SD)                                                                    
   FEV~1~ (%)                                                                                53.1 (±18.4)
   FVC (%)                                                                                   85.9 (±16.9)
   ΔFEV~1~, %                                                                                6.4 (±9.2)
   RV/TLC (%)                                                                                49.5 (±16.0)
  DL~CO~ (%)                                                                                 83.9 (±23.3)
  GOLD classification, n (%)                                                                 
   A (low risk, less symptoms)                                                               27 (22.9%)
   B (low risk, more symptoms)                                                               45 (38.1%)
   C (high risk, less symptoms)                                                              13 (11.0%)
   D (high risk, more symptoms)                                                              33 (28.0%)
  Patients with acute exacerbation, n (%)                                                    
   Moderate                                                                                  23 (19.5%)
   Severe                                                                                    15 (12.7%)
  Number of acute exacerbations[\*](#tfn1-copd-10-1343){ref-type="table-fn"}, mean (range)   
   Moderate                                                                                  0.27 (0--4)
   Severe                                                                                    0.19 (0--3)
  ------------------------------------------------------------------------------------------ --------------

**Note:**

Frequency of acute exacerbation reported by patients and medical chart during the study period.

**Abbreviations:** BMI, body mass index; COPD, chronic obstructive pulmonary disease; DL~CO~, carbon monoxide diffusing capacity; FEV~1~, forced expiratory volume in 1 second; ΔFEV~1~, post bronch-odilator FEV~1~ change; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council dyspnea scale; RV, residual volume; TLC, total lung capacity.

###### 

Demographic and spirometric characteristics according to GOLD classification

                                                A (n=27), (low risk, less symptoms)   B (n=45), (low risk, more symptoms)   C (n=13), (high risk, less symptoms)   D (n=33), (high risk, more symptoms)   *P*-value
  --------------------------------------------- ------------------------------------- ------------------------------------- -------------------------------------- -------------------------------------- -----------
  Age, mean (± SD)                              67.8 (±9.5)                           69.5 (±8.2)                           70.8 (±9.7)                            69.2 (±8.8)                            0.773
  Sex (M:F)                                     26:1                                  40:5                                  13:0                                   31:2                                   0.438
  Follow-up duration (months), mean (± SD)      11.5 (±6.2)                           15.0 (±4.9)                           13.3 (±5.8)                            15.9 (±4.5)                            0.008
  BMI (kg/m^2^), mean (± SD)                    23.0 (±4.1)                           22.1 (±2.9)                           21.6 (±2.9)                            21.6 (±2.9)                            0.389
  Dyspnea (mMRC), mean (± SD)                   1.00 (±0.00)                          2.16 (±0.37)                          1.00 (±0.00)                           2.36 (±0.55)                           \<0.001
  Spirometry, mean (± SD)                                                                                                                                                                                 
   FEV~1~ (%)                                   72.9 (±12.2)                          69.9 (±11.2)                          62.7 (±19.3)                           43.4 (±12.9)                           \<0.001
   FVC (%)                                      91.0 (±14.5)                          92.1 (±18.5)                          88.9 (±14.3)                           76.3 (±17.9)                           0.001
   ΔFEV~1~, %                                   5.2 (±6.2)                            5.1 (±8.6)                            7.9 (±7.8)                             8.4 (±11.8)                            0.374
   RV/TLC (%)                                   45.5 (±12.1)                          46.5 (±10.8)                          40.0 (±5.2)                            59.2 (±22.2)                           0.061
   DL~CO~ (%)                                   91.0 (±22.9)                          85.6 (±15.9)                          70.8 (±28.5)                           79.0 (±27.8)                           0.159
  Patients with acute exacerbation, n (%)                                                                                                                                                                 
   Moderate                                     3 (11.1%)                             3 (6.7%)                              6 (46.2%)                              11 (33.3%)                             0.001
   Severe                                       0                                     0                                     2 (15.4%)                              13 (39.4%)                             \<0.001
  Number of acute exacerbations, mean (range)                                                                                                                                                             
   Moderate                                     0.11 (0--1)                           0.07 (0--1)                           0.69 (0--2)                            0.52 (0--4)                            \<0.001
   Severe                                       0                                     0                                     0.31 (0--3)                            0.58 (0--3)                            \<0.001

**Abbreviations:** BMI, body mass index; DL~CO~, carbon monoxide diffusing capacity; FEV~1~, forced expiratory volume in 1 second; ΔFEV~1~, post bronchodilator FEV~1~ change; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council dyspnea scale; RV, residual volume; TLC, total lung capacity.

###### 

RFS and RSI according to risk and symptoms

  -------------------------------------------------------------------------------------------------------------------------------------------------
  GOLD classification                                       Low risk\      High risk\     *P*-value   Less symptoms\   More symptoms\   *P*-value
                                                            (n=72)         (n=46)                     (n=40)           (n=78)           
  --------------------------------------------------------- -------------- -------------- ----------- ---------------- ---------------- -----------
  RFS                                                                                                                                   

   RFS \>7                                                  30 (41.7%)     19 (41.3%)     0.562       17 (42.5%)       32 (41.0%)       0.516

   Total                                                    6.79 (±2.65)   6.96 (±2.54)   0.736       6.90 (±2.78)     6.83 (±2.52)     0.899

   Subglottic edema                                         1.53 (±0.86)   1.74 (±0.68)   0.160       1.55 (±0.85)     1.64 (±0.77)     0.571

   Vocal fold edema                                         1.00 (±0.87)   1.00 (±0.89)   0.942       0.98 (±0.86)     1.01 (±0.89)     0.824

   Ventricular obliteration                                 1.33 (±1.01)   1.13 (±1.00)   0.287       1.35 (±1.05)     1.21 (±0.99)     0.471

   Diffuse laryngeal edema                                  1.44 (±0.77)   1.09 (±0.87)   0.025       1.45 (±0.93)     1.23 (±0.76)     0.171

   Erythema/hyperemia                                       0.03 (±0.24)   0.22 (±0.76)   0.050       0.05 (±0.32)     0.13 (±0.59)     0.350

   Posterior commissure hypertrophy                         1.21 (±0.65)   1.39 (±0.54)   0.099       1.18 (±0.59)     1.33 (±0.62)     0.180

   Thick mucus                                              0.25 (±0.67)   0.39 (±0.80)   0.302       0.35 (±0.77)     0.28 (±0.70)     0.641

   Granuloma                                                0              0              --          0                0                --

  RSI                                                                                                                                   

   RSI \>13                                                 1 (1.4%)       5 (10.9%)      0.032       1 (2.5%)         5 (6.4%)         0.340

   RSI \>8.5[\*](#tfn4-copd-10-1343){ref-type="table-fn"}   8 (11.1%)      9 (19.6%)      0.152       1 (2.5%)         16 (20.5%)       0.006

  Total                                                     4.07 (±3.26)   5.36 (±6.33)   0.153       3.54 (±2.98)     5.09 (±5.32)     0.047
  -------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

RSI value calculated with receiver operating characteristic curve which is expected to be compatible with RFS 7. Data are presented as mean ± SD, unless otherwise specified.

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; RFS, reflux finding score; RSI, reflux symptom index.

###### 

Multivariate analysis for association between indices of reflux and severe acute exacerbation/mMRC[\*](#tfn6-copd-10-1343){ref-type="table-fn"}

  Variables                       Odds ratio   95% CI        Beta    *P*-value
  ------------------------------- ------------ ------------- ------- -----------
  **Severe acute exacerbation**                                      
  FEV~1~ (%)                      0.95         0.91--0.98    −0.06   0.009
  RSI                             1.15         1.01--1.30    0.14    0.031
  RSI (≤13 versus \>13)           0.08         0.01--0.58    −2.47   0.012
  RFS                             1.29         1.00--1.67    0.26    0.047
  RFS (≤7 versus \>7)             2.40         0.79--7.35    0.88    0.122
  **mMRC**                                                           
  FEV~1~ (%)                      0.01         −0.02--0.01   −0.35   \<0.001
  RSI                             0.03         0.003--0.06   0.21    0.028
  RSI (≤13 versus \>13)           0.49         −0.09--1.08   0.16    0.104
  RFS                             0.01         −0.07--0.01   0.04    0.682
  RFS (≤7 versus \>7)             0.01         −0.24--0.27   0.01    0.098

**Notes:**

Adjusted with age, sex, and BMI. RSI and RFS were tested in separate models due to their interaction.

**Abbreviations:** BMI, body mass index; CI, confidence interval; FEV~1~, forced expiratory volume in 1 second; mMRC, modified Medical Research Council dyspnea scale; RFS, reflux finding score; RSI, reflux symptom index.

###### 

Comparison of RFS between patients with COPD and normal controls matched for age and sex

  RFS variables                                                                   COPD (n=32)   Normal (n=32)   *P*-value
  ------------------------------------------------------------------------------- ------------- --------------- -----------
  Subglottic edema[\*](#tfn8-copd-10-1343){ref-type="table-fn"}                                                 
   0                                                                              4 (12.5%)     17 (53.1%)      0.001
   2                                                                              28 (87.5%)    15 (46.9%)      
  Vocal fold edema[\*](#tfn8-copd-10-1343){ref-type="table-fn"}                                                 
   0                                                                              12 (37.5%)    26 (81.3%)      0.003
   1                                                                              9 (28.1%)     4 (12.5%)       
   2                                                                              9 (28.1%)     1 (3.1%)        
   3                                                                              2 (6.3%)      1 (3.1%)        
   4                                                                              0             0               
  Ventricular obliteration[\*](#tfn8-copd-10-1343){ref-type="table-fn"}                                         
   0                                                                              12 (37.5%)    27 (84.4%)      ,0.001
   2                                                                              20 (62.5%)    5 (15.6%)       
   4                                                                              0             0               
  Diffuse laryngeal edema[\*](#tfn8-copd-10-1343){ref-type="table-fn"}                                          
   0                                                                              6 (18.8%)     16 (50.0%)      0.008
   1                                                                              14 (43.7%)    14 (43.7%)      
   2                                                                              10 (31.2%)    2 (6.3%)        
   3                                                                              2 (6.3%)      0               
   4                                                                              0             0               
  Erythema/hyperemia                                                                                            
   0                                                                              31 (96.9%)    30 (93.7%)      0.500
   2                                                                              1 (3.1%)      2 (6.3%)        
   4                                                                              0             0               
  Posterior commissure hypertrophy[\*](#tfn8-copd-10-1343){ref-type="table-fn"}                                 
   0                                                                              1 (3.1%)      12 (37.5%)      0.005
   1                                                                              18 (56.3%)    14 (43.8%)      
   2                                                                              12 (37.5%)    5 (15.6%)       
   3                                                                              1 (3.1%)      1 (3.1%)        
   4                                                                              0             0               
  Thick mucus                                                                                                   
   0                                                                              28 (87.5%)    28 (87.5%)      0.650
   2                                                                              4 (12.5%)     4 (12.5%)       
  Granuloma                                                                                                     
   0                                                                              32 (100%)     32 (100%)       NA
   2                                                                              0             0               

**Note:**

Significantly predominant in COPD patients.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; NA, not applicable; RFS, reflux finding score.

[^1]: These authors contributed equally to this work
